GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Scopus Biopharma SCPS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2022

Net income

−$11.6m

FY2018FY2022

Free cash flow

−$8.1m

FY2018FY2022

Shareholders' equity

−$7.1m

FY2018FY2022

Income statement

Fiscal years

FY2022FY2021FY2020FY2019FY2018
Research and development$2.7m$15.0m$7.4m$463,111$277,539
Operating income−$11.7m−$27.6m−$10.2m−$2.7m−$685,964
Net income−$11.6m−$25.5m−$11.6m−$2.7m−$685,964
Diluted earnings per share-0.55-1.21-0.77-0.18-0.05

Balance sheet

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018
Total assets$392,265$8.2m$2.0m$771,682$132,638
Cash and short-term investments$124,575$7.9m$1.8m$36,747$1,660
Total liabilities$7.5m$4.2m$3.8m$854,541$137,964
Debt——$2.3m——
Shareholders' equity−$7.1m$4.0m−$1.8m−$82,859−$5,326
Shares outstanding21m21m15m15m15m

Cash flow

Fiscal years

FY2022FY2021FY2020FY2019FY2018
Cash from operations−$8.1m−$11.4m−$2.5m−$2.1m−$747,317
Capital spending−$1,552−$1,999−$1,999−$4,251−$4,251
Free cash flow−$8.1m−$11.4m−$2.5m−$2.1m−$751,568

Latest quarters

By quarter end

Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022Dec 2021Sept 2021
Operating income−$2.9m−$1.8m−$1.8m−$1.9m−$3.3m−$6.5m−$6.5m−$2.8m
Net income−$2.6m−$1.7m−$1.7m−$1.9m−$3.3m−$6.5m−$6.5m−$1.4m
Diluted earnings per share-0.12-0.08-0.08-0.09-0.16-0.31-0.31-0.07
Cash from operations−$1.0m———−$2.0m−$4.0m−$4.0m−$2.0m
Capital spending—−$1.0m——————
Total assets$497,554$392,265$392,265$415,676$1.7m$8.2m$8.2m$4.0m
Cash and short-term investments—$124,575—$310,821$1.2m$7.9m—$3.6m
Shareholders' equity−$9.5m−$6.6m−$6.6m−$5.5m−$3.7m$4.0m$4.0m$1.8m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income63.3%——
Net income62.8%——

Share price return

Finished calendar years

202520242023202220212020
Return641%8996%40%-83%-87%331%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.